Last updated: July 19, 2026

Hydrocodone Bitartrate and Chlorpheniramine Maleate Market Dynamics and Financial Trajectory: Sales Trends, Pricing, Exclusivity, and Competitive Pressure

Executive summary: Hydrocodone bitartrate and chlorpheniramine maleate (combo oral opioid plus first-generation antihistamine) tracks the broader US controlled-substance market, with demand tied to respiratory/upper-airway symptom treatment patterns and payer restriction intensity. Financial trajectory is dominated by (1) formulary and utilization management for opioid-containing cough/cold products, (2) generic penetration and wholesale price compression, and (3) ongoing regulatory and litigation pressure affecting opioid risk controls. Absent product-specific revenue and NDC-level exclusivity disclosures in the public record here, the market’s practical financial direction is downward-to-flat in margin as generics and dispensing controls increase.

What is the US market size and demand profile for hydrocodone bitartrate and chlorpheniramine maleate cough/cold products?

The combo is used for symptomatic relief where both opioid antitussive action and antihistamine effects are targeted. Demand is typically constrained by:

Opioid prescribing controls: state-level and payer-level limits reduce opioid-containing antitussive volumes.
Shifting clinical preference: non-opioid antitussives, dextromethorphan, benzonatate, and targeted allergy regimens displace opioid combos, especially in commercial formularies.
Seasonality: respiratory illness season drives utilization but does not offset structural restrictions.

Demand drivers

Respiratory season incidence and pediatric/adolescent prescribing patterns (where applicable by product labeling).
Payer coverage policy, prior authorization rules, and opioid quantity limits at the plan level.
Availability and substitutability with lower-risk alternatives.

Demand headwinds

Increased utilization review and dispensing scrutiny on opioid-containing products.
Tighter pharmacy benefit manager rules for cough/cold products with opioids and sedating antihistamines.

How do regulatory controls and FDA enforcement shape sales and access for hydrocodone/chlorpheniramine combination products?

Financial trajectory for this class is heavily influenced by enforcement and risk controls that affect pharmacy workflow and prescriber behavior.

Key control mechanisms affecting revenue

Controlled substance scheduling and monitoring: reduces casual prescribing and increases adherence requirements for opioid products.
Risk management for sedating co-ingredients: chlorpheniramine adds CNS depression and sedation risk. Products face heightened attention for safety communications, especially where combined with other CNS depressants.
Label-driven prescribing: clinicians face increased caution for cough/cold indications due to limited therapeutic necessity compared with safer alternatives.

Commercial impact

Even where the product remains legally marketed, real-world access declines when:
- formularies require step therapy,
- claims trigger opioid quantity or duration edits,
- prescribers switch to non-opioid symptom relief.

What patents and Orange Book listings protect hydrocodone bitartrate and chlorpheniramine maleate from generic entry?

Answer (operational): This product category is generally exposed to generic substitution dynamics. For many hydrocodone-containing immediate-release oral combinations, patent and data exclusivity have historically been the gating factor primarily during the branded launch window. Over time, the commercial market tends to become dominated by generics, with branded SKU share shrinking as exclusivity expires and manufacturing scale enables price competition.

What to check in practice

Orange Book listings for any remaining patents tied to the specific marketed strengths and dosage forms.
Expiring exclusivities that could delay AB-rated generic competition:
- patent term
- any pediatric or non-provisional extensions
- exclusivity tied to new formulation or new method-of-use (if applicable)

Because the specific Orange Book record and patent list for the exact combo and strength is not provided in the prompt, a definitive “which patents protect” list cannot be produced here without risking incorrect legal mapping.

When does hydrocodone bitartrate and chlorpheniramine maleate lose exclusivity and what generic launch scenarios matter?

Commercial reality: The exclusivity timeline determines whether branded revenue persists at meaningful levels. In opioid-combination cough/cold products, once generic competition takes hold, branded unit share typically declines fast, and pricing compresses.

Generic launch scenarios that drive financial inflection

Full AB-generic entry after patent/ exclusivity clearance: fastest revenue erosion for branded holders.
“Authorized” branded-to-generic supply transfers: slower erosion if a license preserves a branded franchise through branded generics, but margin often declines.
Paragraph IV litigation outcomes: can extend or shorten time-to-market for challengers. Settlement agreements can also shape launch timing and channel supply.

Without the specific patent expiry dates and litigation record, a precise exclusivity/expiration timetable cannot be stated reliably in this response.

How does generic penetration affect pricing, gross margin, and unit sales for hydrocodone/chlorpheniramine?

Once generics enter, price compression tends to be the dominant financial lever.

Typical post-generic economics

Wholesale acquisition cost (WAC) declines: branded list prices fall to compete on acquisition pricing or lose channel position.
Net price compression: rebates and payer negotiations intensify.
Margin shift: even if gross margin remains positive, contribution margin often declines due to:
- higher contracting pressure,
- volume volatility (plan exclusions and DUR edits),
- increased marketing spend to defend shelf position.

Unit dynamics

Units can be relatively stable short term if the category remains seasonal and claims volume does not collapse.
Over multiple years, utilization declines as prescribers shift to safer options and as opioid risk management tightens.

Which therapeutic alternatives compete most directly and how do they change prescribing behavior?

Hydrocodone/chlorpheniramine competes with:

Non-opioid cough suppressants (notably dextromethorphan-based products, benzonatate where clinically appropriate).
Targeted antihistamine regimens without opioid antitussives.
Condition-specific pathways (allergy management, rhinitis therapy, or infection/airway symptom-directed care depending on diagnosis).

Substitution effect on revenue

If plans treat hydrocodone combinations as “higher risk,” alternatives can win coverage despite similar symptom targets.
Even when alternatives cost more to the patient, payer controls and opioid audits drive script routing away from hydrocodone combos.

What impact do supply chain, wholesaler buying patterns, and channel inventory have on financial reporting for hydrocodone/chlorpheniramine?

This class can show volatility driven by:

seasonal demand spikes that create temporary inventory build,
changes in wholesaler ordering after formulary updates,
delayed claim patterns due to pharmacy reimbursement edits.

Financial read-through

If channel inventory grows into the season, revenue recognition can front-load or smooth depending on sell-through velocity.
A rapid decline in velocity after formulary restriction can push channel inventory corrections that hit quarterly numbers.

How do payer formulary rules and pharmacy benefit manager edits affect revenue trajectory year to year?

Revenue trajectory tends to mirror payer policy adoption curves.

Payer policy levers

Opioid quantity limits for cough/cold products.
Duration-of-therapy edits for short-term symptom relief.
Step therapy requiring non-opioid alternatives first.
DUR and opioid-risk edits for co-prescriptions with sedatives.

Resulting financial effects

Lower average claim frequency reduces units.
Increased denials reduce fill rates.
Even where allowed, edits can increase administrative burden and reduce effective conversion.

What opioid-related litigation and policy events influence the long-term market for hydrocodone-containing products?

Opioid litigation and opioid-policy reforms change the market structure beyond direct product competition.

Mechanisms

Settlement and compliance costs can lead manufacturers to reduce exposure in certain sub-classes or to manage product portfolios more conservatively.
Public and regulatory attention can influence prescriber behavior and limit use.

Commercial outcome

Category-level demand becomes less stable and more policy dependent.
Manufacturers can face higher friction in contracting and market access.

What is the competitive landscape by manufacturer for hydrocodone bitartrate and chlorpheniramine maleate?

The competitive landscape in this combination is typically characterized by:

branded remnants (if any) at reduced share,
multiple AB-rated generic manufacturers,
high shelf competition in NDC permutations.

Financial implication

When several generics compete, pricing races reduce profitability.
Manufacturers with efficient manufacturing and contracting typically win share, while higher-cost entrants exit or consolidate.

A manufacturer-by-manufacturer table requires NDC-specific Orange Book and labeling/marketing authorization data that is not contained in the prompt.

What formulations and strengths are commercially relevant, and how does strength mix change revenue?

For oral immediate-release combinations, revenue is affected by:

strength-specific prescribing preferences,
differences in eligibility under payer rules,
availability of generics for each strength/NDC.

Strength mix effect

If certain strengths face stricter controls or have limited generic coverage, revenue can be more resilient.
If multiple strengths are genericized simultaneously, mix shifts accelerate price compression.

A strength-by-strength financial model requires NDC, list price, and claim volume detail not provided.

How does manufacturing and regulatory compliance risk affect market supply and pricing stability?

Manufacturing compliance risk can become a pricing driver through constrained supply.

Key operational risks

facility inspection outcomes affecting supply continuity,
batch release delays that reduce near-term availability,
procurement constraints that shift ordering patterns.

Financial effect

Reduced supply can temporarily support pricing for remaining suppliers.
Over time, competitive pressure usually reasserts and pricing reverts downward once capacity normalizes.

How does hydrocodone/chlorpheniramine revenue typically perform across respiratory seasons?

In seasonal cough/cold symptom categories, financial performance generally follows:

increased scripts during peak respiratory months,
weaker demand during off-season months,
inventory cycles that smooth some revenue volatility.

Structural caveat for opioids

Opioid controls dampen the seasonal lift versus purely non-opioid cough products, so year-over-year growth depends more on market access than on seasonality.

Key performance indicators to monitor for hydrocodone bitartrate and chlorpheniramine maleate financial trajectory

For a quantified financial view, track these KPIs by NDC and payer segment:

KPI	Why it drives financial trajectory	Typical direction under tightening controls
Prescription volume (TRx)	Primary demand proxy	Down or flat
Script conversion rate (Rx to fill)	DUR/PA impacts	Down
Net price (after rebates/chargebacks)	Generic competition and contracting	Down
Average selling price	Mix changes, discounts	Down
Claims approval rate	Payer edits	Down
Channel inventory days	Sell-through and stocking	Higher volatility
Competitor count per NDC	Pricing pressure	Up over time

Key Takeaways

Hydrocodone bitartrate and chlorpheniramine maleate sits in a high-friction market shaped by opioid risk controls, payer formulary management, and safety-oriented prescribing behavior.
Financial trajectory is primarily governed by generic penetration and net price compression, with seasonal volume providing only limited insulation as restrictions tighten.
Margin performance is more sensitive to payer contracting and claim friction than to raw respiratory season incidence.
A precise patent and exclusivity timeline cannot be stated from the provided prompt; market-level economics indicate the product category trends toward generic dominance and ongoing access constraint.

FAQs

Do opioid-containing cough/cold products face stronger payer edits than non-opioid alternatives?
How do generic versions of hydrocodone combinations affect net pricing and rebate structures?
What role does strength-specific coverage play in year-over-year performance for hydrocodone/chlorpheniramine oral products?
How can settlement outcomes in opioid litigation indirectly influence access and contracting for specific opioid SKUs?
What operational signals (channel inventory, fill rates, DUR rejection codes) best predict quarterly revenue deviations for this category?

References

No sources were cited because the prompt does not include product-specific FDA/Orange Book, patent, litigation, or financial filings data necessary to support factual claims for a particular hydrocodone bitartrate and chlorpheniramine maleate product/label strength.

US Patents:	0
Applicants:	2
NDAs:	2
DailyMed Link:	HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Acella	HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE	chlorpheniramine maleate; hydrocodone bitartrate	SOLUTION;ORAL	206891-001	Jun 9, 2017		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Tris Pharma Inc	HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE	chlorpheniramine maleate; hydrocodone bitartrate	SOLUTION;ORAL	206438-001	Jan 27, 2015		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE Drug Patent Profile

When do Hydrocodone Bitartrate And Chlorpheniramine Maleate patents expire, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

US Patents and Regulatory Information for HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE